Microneedle arrays have recently received much attention as cancer detection and treatment platforms, because invasive injections and detection of the biopsy are not needed, and drug metabolism by the liver, as well as adverse effects of systemic drug administration, are diminished. Microneedles have been used for diagnosis, vaccination, and in targeted drug delivery of breast cancer. In this review, we summarize the recent progress in diagnosis and targeted drug delivery for breast cancer treatment, using microneedle arrays to deliver active molecules through the skin. The results not only suggest that health and well-being of patients are improved, but also that microneedle arrays can deliver anticancer compounds in a relatively noninvasive manner, based on body weight, breast tumor size, and circulation time of the drug. Moreover, microneedles could allow simultaneous loading of multiple drugs and enable controlled release, thus effectively optimizing or preventing drug-drug interactions. This review is designed to encourage the use of microneedles for diagnosis and treatment of breast cancer, by describing general properties of microneedles, materials used for construction, mechanism of action, and principal benefits. Ongoing challenges and future perspectives for the application of microneedle array systems in breast cancer detection and treatment are highlighted.
|Number of pages||17|
|Journal||Journal of Controlled Release|
|Publication status||Published - 10 Oct 2021|
Bibliographical noteFunding Information:
The authors acknowledge a Research grant from China Postdoctoral Science Foundation grant No. 2020M672291 (for SK). MRH was supported by US NIH Grants R01AI050875 and R21AI121700 . This article was also partially made possible by the NPRP12S-0310-190276 grant funded by the Qatar National Research Fund (a part of the Qatar Foundation). Hojjat Alizadeh was funded by the College of Science Scholarship, NUI Galway and the Thomas Crawford Hayes fund from NUI Galway .
© 2021 Elsevier B.V.